We are a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. Our strategy is to create a sustainable portfolio of ophthalmic products by leveraging our commercial capabilities and pipeline assets and pursuing corporate development and licensing opportunities. Our specialty eye care sales force generates revenue from the promotion ofAzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis and the co-promotion ofElestat (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis. We receive royalties based on net sales ofRestasis(cyclosporine ophthalmic emulsion) 0.05% for dry eye and expect to begin receiving royalties in 2011 based on net sales ofDiquas Ophthalmic Solution 3% (diquafosol tetrasodium) for dry eye in Japan.
Company profile
Ticker
ISPH
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43209022
Latest filings (excl ownership)
CT ORDER
Confidential treatment order
3 Jun 11
CT ORDER
Confidential treatment order
3 Jun 11
15-12G
Securities registration termination
16 May 11
25-NSE
Exchange delisting
16 May 11
8-K
Completion of Acquisition or Disposition of Assets
16 May 11
EFFECT
Notice of effectiveness
16 May 11
EFFECT
Notice of effectiveness
16 May 11
POS AM
Prospectus update (post-effective amendment)
16 May 11
POS AM
Prospectus update (post-effective amendment)
16 May 11
S-8 POS
Registration of securities for employees (post-effective amendment)
16 May 11